— Flowchart of steps necessary to differentiate between subgroups of malignancy and extent of disease within gynaecological oncology centres. *Early stage and advanced stage might differ according to different ADNEX models (Stage I vs Stages II–IV) and oncologically (Stages I–II vs Stages I–IV). αFP, alpha-fetoprotein; AMH, anti-Müllerian hormone; CA 125, cancer antigen 125; CA 15-3, cancer antigen 15-3; CA 19.9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; CT, computed tomography; hCG, human chorionic gonadoptrophin; IOTA ADNEX, International Ovarian Tumour Analysis Group Assessment of Different Neoplasias in the adneXa; LDH, lactate dehydrogenase; MRI, magnetic resonance imaging; PET-CT, positron emission tomography-computed tomography.